---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-002605"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:38:33.060832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals licenses U.S. rights to ultra-rare disease candidate; FDA under review

## Summary
- Licensed product is first/only generic alternative for condition affecting <100 U.S. patients.
- Product currently under FDA review; expected approval and launch mid-2026.
- Deal aligns with Eton's commercial infrastructure; adds to pipeline of ultra-rare disease products.
- CEO cites opportunity to bring improved patient experience via Eton Cares program.
- Eton has eight commercial rare disease products and five late-stage candidates.

## SEC filing metadata
- accession: 0001437749-26-002605
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926002605/0001437749-26-002605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926002605/eton20260130_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-002605
- JSON: https://secwatch.observer/filing/0001437749-26-002605.json
- Plain text: https://secwatch.observer/filing/0001437749-26-002605.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.